36X Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.16 |
| 52 Week High | HK$3.18 |
| 52 Week Low | HK$1.86 |
| Beta | 1.17 |
| 1 Month Change | 8.00% |
| 3 Month Change | -28.00% |
| 1 Year Change | -8.47% |
| 3 Year Change | -56.80% |
| 5 Year Change | n/a |
| Change since IPO | -37.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 36X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.5% | 0.4% | -1.7% |
| 1Y | -8.5% | -24.6% | 6.2% |
Return vs Industry: 36X exceeded the German Biotechs industry which returned -24.6% over the past year.
Return vs Market: 36X underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| 36X volatility | |
|---|---|
| 36X Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 36X's share price has been volatile over the past 3 months.
Volatility Over Time: 36X's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 583 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| 36X fundamental statistics | |
|---|---|
| Market cap | €641.19m |
| Earnings (TTM) | -€118.24m |
| Revenue (TTM) | €28.36m |
22.6x
P/S Ratio-5.4x
P/E RatioIs 36X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 36X income statement (TTM) | |
|---|---|
| Revenue | CN¥221.98m |
| Cost of Revenue | CN¥30.54m |
| Gross Profit | CN¥191.44m |
| Other Expenses | CN¥1.12b |
| Earnings | -CN¥925.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | 86.24% |
| Net Profit Margin | -416.98% |
| Debt/Equity Ratio | 2,510.1% |
How did 36X perform over the long term?
See historical performance and comparison